Insider Selling: United Therapeutics (NASDAQ:UTHR) CEO Sells $5,386,880.00 in Stock

United Therapeutics Corporation (NASDAQ:UTHR) CEO Martine Rothblatt sold 9,500 shares of the firm’s stock in a transaction dated Monday, May 18th. The shares were sold at an average price of $567.04, for a total transaction of $5,386,880.00. Following the completion of the sale, the chief executive officer owned 40,513 shares of the company’s stock, valued at $22,972,491.52. This trade represents a 19.00% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

United Therapeutics Stock Up 0.3%

Shares of NASDAQ UTHR opened at $565.87 on Friday. United Therapeutics Corporation has a 52 week low of $272.12 and a 52 week high of $609.35. The firm has a 50-day moving average price of $562.78 and a 200 day moving average price of $511.17. The stock has a market capitalization of $24.02 billion, a price-to-earnings ratio of 20.89, a price-to-earnings-growth ratio of 1.82 and a beta of 0.60.

United Therapeutics (NASDAQ:UTHR) last announced its quarterly earnings data on Wednesday, May 6th. The biotechnology company reported $5.82 EPS for the quarter, missing the consensus estimate of $7.00 by ($1.18). United Therapeutics had a net margin of 40.62% and a return on equity of 19.24%. The company had revenue of $781.50 million during the quarter, compared to analyst estimates of $797.40 million. During the same quarter last year, the business earned $6.63 EPS. The firm’s revenue for the quarter was down 1.6% on a year-over-year basis. Equities research analysts expect that United Therapeutics Corporation will post 27.07 EPS for the current fiscal year.

Institutional Investors Weigh In On United Therapeutics

A number of institutional investors have recently bought and sold shares of UTHR. Geneos Wealth Management Inc. grew its holdings in United Therapeutics by 141.7% in the first quarter. Geneos Wealth Management Inc. now owns 145 shares of the biotechnology company’s stock valued at $45,000 after purchasing an additional 85 shares during the period. Northwestern Mutual Wealth Management Co. grew its holdings in United Therapeutics by 18.8% in the second quarter. Northwestern Mutual Wealth Management Co. now owns 443 shares of the biotechnology company’s stock valued at $127,000 after purchasing an additional 70 shares during the period. Jump Financial LLC purchased a new stake in United Therapeutics in the second quarter valued at approximately $277,000. Cerity Partners LLC grew its holdings in United Therapeutics by 77.3% in the second quarter. Cerity Partners LLC now owns 12,843 shares of the biotechnology company’s stock valued at $3,691,000 after purchasing an additional 5,600 shares during the period. Finally, Bank of Nova Scotia grew its holdings in United Therapeutics by 6.9% in the second quarter. Bank of Nova Scotia now owns 1,628 shares of the biotechnology company’s stock valued at $468,000 after purchasing an additional 105 shares during the period. 94.08% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several analysts recently commented on UTHR shares. Jefferies Financial Group reiterated a “buy” rating on shares of United Therapeutics in a research note on Monday, March 2nd. Royal Bank Of Canada reduced their price objective on shares of United Therapeutics from $707.00 to $701.00 and set an “outperform” rating for the company in a research note on Thursday, May 7th. TD Cowen restated a “buy” rating on shares of United Therapeutics in a research report on Thursday. HC Wainwright lifted their target price on shares of United Therapeutics from $600.00 to $660.00 and gave the stock a “buy” rating in a research report on Tuesday, March 31st. Finally, Bank of America lifted their target price on shares of United Therapeutics from $569.00 to $626.00 and gave the stock a “neutral” rating in a research report on Tuesday, March 31st. Eleven investment analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. According to data from MarketBeat, United Therapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $619.42.

About United Therapeutics

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.